We Revolutionized the KLH Industry
Stellar Biotechnologies began in 1999 as a private company in Port Hueneme, California, USA.
At that time, a paradigm shift in drug research – toward treatment strategies that focus the body’s own immune system to target disease – pointed to rising demand for KLH protein. This brought attention to an unsustainable situation: fishery and manufacturing practices threatened to deplete the scarce marine source of KLH and constrain future supply of this important pharmaceutical ingredient.
Stellar was founded to address the need for sustainable, commercial-scale supplies of high-quality KLH.
Initially supported by grants from the National Institutes of Health (NIH), the National Science Foundation (NSF), and the California Technology Investment Partnership (CalTIP), Stellar developed proprietary, industry-leading KLH technology and facilities.
We revolutionized KLH manufacturing with ground-breaking aquaculture science and environmentally sound methods that transformed a threatened natural resource into a viable commercial platform. We leveraged this expertise into a portfolio of Stellar KLH™ products including carrier protein for vaccine conjugation, finished product for immune stimulation in immunotoxicology applications, and novel assays.
Today, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is a publicly-held corporation specializing in the development, manufacturing and commercialization of KLH products and KLH-based immunotherapies.
We are the leader in sustainable KLH manufacture with important intellectual property related to aquaculture systems, cultivation and protection of the Giant Keyhole Limpet (Megathura crenulata), and the production of GMP grade KLH protein.